Connect
← Return to Orgovyx and Cyberknife
Discussion
Comment receiving replies
Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used). (See the attached NCCN guidelines for favorable intermediate risk prostate cancer.) (However, with a Gleason 7(4+3) (unfavorable intermediate), the NCCN guidelines recommend 4-6 months of ADT.)
> Do you have additional risk factors?
> With your 3+4, what is the % of “4”?
Actually, Orgovyx has the least risk of cardiovascular events of the ADTs they could’ve chosen. (The HERO study for Orgovyx showed significantly lower major adverse cardiovascular events with Orgovyx compared to leuprolides (Lupron, Eligard, etc.).
Replies to "Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used)...."
Yes. Tonsil cancer survivor. They did an AI review of my biopsy:
At your consult appointment, we talked about running a test called Artera AI on your biopsy sample to help us determine if the hormone therapy would be beneficial to you. We have the results and it shows that the biopsy sample is positive for the ADT biomarker, meaning that you would benefit from the hormone blocking therapy.
Yahoo Mail: Search, Organize, Conquer
Here is the 7 biopsy result:
Prostate, right, core biopsy
Histologic Type: Acinar adenocarcinoma
Histologic Grade (Gleason Pattern)
Primary (Predominant) Pattern: Grade 3
Secondary (Worst Remaining) Pattern: Grade 4
Total Gleason Score: 7
Grade Group: 2
Connect
@brianjarvis NCCN guidelines for favorable intermediate risk prostate cancer